VLI-02B

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameVLI-02B
Drug Alias NameAd.CEA.CD40Ldual CD40 costimulator/CEA antigen (shielded adenoviral vector vaccine) (VectorLogics/DNAtrix)modified and shielded adenovirus recombinant vector vaccine (VectorLogics)modified and shielded adenovirus recombinant vector vaccine (DNAtrix)VLI-02B
ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonistsCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVectorlogics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVectorlogicsDnatrix Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A